Status:
COMPLETED
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
Lead Sponsor:
Children's Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Ewing Sarcoma of Bone
Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Eligibility:
All Genders
Up to 30 years
Phase:
NA
Brief Summary
This clinical trial is studying the side effects of combination chemotherapy and to see how well they work in treating patients with newly diagnosed localized Ewing sarcoma family of tumors. Drugs use...
Detailed Description
PRIMARY OBJECTIVES: I. To assess the feasibility and safety of adding interval-compressed vincristine, topotecan hydrochloride, and cyclophosphamide to a treatment protocol utilizing interval compres...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosis of extracranial Ewing sarcoma or peripheral primitive neuroectodermal tumor of bone or soft tissue:
- Newly diagnosed disease
- Disease confirmed by biopsy only with no attempt at complete or partial resection
- Unplanned excision allowed provided adequate imaging was obtained prior to surgery and incompletely resected disease is controlled by local therapy
- No esthesioneuroblastoma
- Localized disease, including any of the following sites:
- Chest wall tumors with ipsilateral pleural effusions, ipsilateral positive pleural fluid cytology, or ipsilateral pleural based secondary tumor nodules;
- No contralateral pleural effusions or pleural nodules
- Regional lymph nodes that are clinically suspicious or confirmed by biopsy
- No distant lymph node metastases
- Extra-dural tumors arising in the bony skull
- No tumors arising in the intra-dural soft tissue or the intra-dural region of the spine
- No evidence of metastatic disease, defined as any of the following:
- Lesions that are discontinuous from the primary tumor
- Lesions that are not regional lymph nodes
- Lesions that do not share a body cavity with the primary tumor
- No evidence by CT scan of metastatic lung disease, defined as any of the following:
- One pulmonary nodule \> 1 cm in diameter or more than one nodule \> 0.5 cm diameter
- Pulmonary nodules that are resected and are not found to be metastatic Ewing sarcoma are allowed
- Biopsy proven solitary nodules measuring 0.5 to 1.0 cm or multiple nodules measuring 0.3 to 0.5 cm
- Solitary nodules measuring \< 0.5 cm or multiple nodules measuring \< 0.3 cm are allowed unless biopsy proven to be metastatic (biopsy is not required)
- Karnofsky performance status (PS) 0-2 (\>= 16 years old) OR Lansky PS 0-2 (\< 16 years old)
- Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine based on age/gender as follows:
- 1 month to \< 6 months old (males and females 0.4 mg/dL)
- 6 months to \< 1 year old (males and females 0.5 mg/dL)
- 1 to \< 2 years old (males and females 0.6 mg/dL)
- 2 to \< 6 years old (males and females 0.8 mg/dL)
- 6 to \< 10 years old (males and females 1.0 mg/dL)
- 10 to \< 13 years old (males and females 1.2 mg/dL)
- 13 to \< 16 years old (males 1.5 mg/dL and females 1.4 mg/dL)
- \>= 16 years old (males 1.7 mg/dL and females 1.4 mg/dL)
- AST or ALT \< 2.5 times ULN for age
- Total bilirubin =\< 1.5 times upper limit of normal (ULN) for age
- Shortening fraction of \>= 27% by ECHO or ejection fraction of \>= 50% by radionuclide angiogram (MUGA)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior chemotherapy or radiotherapy
- No concurrent pegfilgrastim (Neulasta) or sargramostim (GM-CSF)
- No other concurrent cancer chemotherapy or immunomodulating agents, including steroids, unless used as an antiemetic
Exclusion
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00618813
Start Date
March 1 2008
Last Update
September 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Oncology Group
Monrovia, California, United States, 91016